EMA press release is here, basically concludes:
- unusual blood clots with low blood platelets should be listed as very rare side effects of the vaccine
- overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects
- HIT-like mechanism is plausible twitter.com/ema_news/statu…
BK Titanji #ILookLikeAScientist
@Boghuma
-
Wed Apr 07
EMA concludes in their report that while these rare AEs are likely linked to A/Z 💉and VIPIT a plausible mechanism, benefits of vaccination still outweigh these risks.
twitter.com/EMA_News/statu…
BK Titanji #ILookLikeAScientist
@Boghuma
-
Wed Apr 07
UK's JCVI in light of this review and emerging pharmacovigilance data now recommending use of an alternative #covid19 vaccine other than #AstraZeneca vaxx in individuals <30 y/o.
gov.uk/government/pub…
222/ 34mill, about 1 per 100000. They haven’t issued age restrictions but left countries to impose their own (which a growing list have done). No risk factors identified meaning no way to predict twitter.com/EMA_News/statu…
Kirby Institute, UNSW Sydney: infectious diseases; hepatitis C; hepatitis B; health for people who use drugs
Open Profile
Key findings from EMA review:
👉 62 CVST & 24 splanchnic (abdominal) vein thrombosis events from 25M AstraZeneca doses
👉 18 (21%) deaths
👉 benefits continue to outweigh risk
So, risk around 1/300K & death 1/1.4M, but need age-specific risks. ema.europa.eu/en/news/astraz…